Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Hansa Biopharma AB ( (SE:HNSA) ) is now available.
Hansa Biopharma announced that its CEO, Renée Aguiar-Lucander, will present at the 16th Annual Pareto Securities Healthcare Conference in Stockholm. The presentation and subsequent panel discussion will address current industry dynamics, including business deals, healthcare system changes, and investor sentiment, potentially impacting the company’s operations and positioning within the biopharmaceutical industry.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK33.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company leverages its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Its portfolio includes imlifidase, which facilitates kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG cleaving molecule.
Average Trading Volume: 420,281
Technical Sentiment Signal: Hold
Current Market Cap: SEK2.48B
For a thorough assessment of HNSA stock, go to TipRanks’ Stock Analysis page.